Abstract
We aimed to investigate the safety and efficacy of dienogest (DNG), a progestational 19-norsteroid, administered for 52weeks in patients with symptomatic adenomyosis. A total of 130 patients with adenomyosis received 2mg of DNG orally each day for 52weeks. In cases of complicated anemia, patients were treated for anemia prior to receiving the medication. Adverse events and adverse drug reactions were evaluated. The patients' pain symptoms (dysmenorrhea and pelvic pain from adenomyosis) were assessed using a pain-scoring tool. This was a verbal rating scale comprising a 0-3-point pain-severity score measuring disability to work, and an analgesics-usage score measuring need for analgesics. The most common adverse drug reactions included metrorrhagia (96.9%) and hot flush (7.7%). However, in most cases, metrorrhagia was tolerable and no clinically significant changes were observed concerning the incidence or severity of reactions during the 52-week treatment period. There were no serious adverse events. Both the pain-severity score and analgesics-usage score decreased after the start of treatment with DNG. The mean±standard deviation changes from baseline for the pain score were -3.4±1.8 at 24weeks and -3.8±1.5 at 52weeks, respectively. The long-term use of DNG was well-tolerated and effective in patients with symptomatic adenomyosis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call